Is there a future for renin inhibitors?

Pharmacological interruption of the renin-angiotensin system is possible at three major sites, the angiotensin-converting enzyme (ACE), the AT1 receptor and at the interaction of renin with its substrate, angiotensinogen. Skeggs and his associates in 1957 argued logically but without prognostic accuracy that ‘since renin is the initial and rate-limiting substance in the renin-angiotensin system, it would seem that the renin inhibition approach would be the most likely to succeed’. In fact, the development of agents that act at all three levels has enjoyed substantial success, yet renin inhibition, which showed early progress in studies in humans, has languished. Our task in this essay is to review the reasons for the slow evolution of renin inhibition and to discuss the potential of such agents in modern pharmacotherapy. All of the structure-action relationships have involved variation on the original peptide structure. The possibility that alternative approaches based on x-ray crystallography and reconstruction of the structure of the active site would lead to novel agents, appears not to have been explored systematically. This opportunity is all the more attractive because renin is one of the few targets that is actually soluble and amenable to x-ray crystallographic studies. At the moment, it appears that all renin inhibitor development programs have been closed, although hints periodically reappear to indicate that one company or another is pursuing a novel agent. The decision to close programs seems to have reflected not the therapeutic potential of renin inhibitors, but rather the cost of their synthesis, continuing problems with bioavailability and the remarkable success of the competitor class - the AngII antagonists. We believe that the potential of renin inhibition in human therapy has been under estimated and still shows substantial promise.

[1]  J. Ménard,et al.  Plasma angiotensins, renin, and blood pressure during acute renin inhibition by CGP 38 560A in hypertensive patients. , 1989, American journal of hypertension.

[2]  T. L. Blundell,et al.  Structural evidence for gene duplication in the evolution of the acid proteases , 1978, Nature.

[3]  E. Haber George C. Griffith lecture. The role of renin in normal and pathological cardiovascular homeostasis. , 1976, Circulation.

[4]  N. Hollenberg,et al.  Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. , 1998, Hypertension.

[5]  R. Cody,et al.  Specific inhibition of renin by an angiotensinogen analog: studies in sodium depletion and renin-dependent hypertension. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[6]  N. Hollenberg,et al.  The paradox of the low-renin state in diabetic nephropathy. , 1999, Journal of the American Society of Nephrology : JASN.

[7]  A. Allen,et al.  Local actions of angiotensin II: quantitative in vitro autoradiographic localization of angiotensin II receptor binding and angiotensin converting enzyme in target tissues. , 1986, Journal of cardiovascular pharmacology.

[8]  M. James,et al.  Stereochemical analysis of peptide bond hydrolysis catalyzed by the aspartic proteinase penicillopepsin. , 1985, Biochemistry.

[9]  N. Fisher,et al.  Renal vascular responses to renin inhibition with zankiren in men , 1995, Clinical pharmacology and therapeutics.

[10]  R. Kopelman,et al.  Antibodies as specific renin inhibitors: studies with polyclonal and monoclonal antibodies and Fab fragments. , 1983, Clinical and experimental hypertension. Part A, Theory and practice.

[11]  N. Hollenberg,et al.  Renal and Endocrine Responses to a Renin Inhibitor, Enalkiren, in Normal Humans , 1991, Hypertension.

[12]  C. Oefner,et al.  Substituted piperidines--highly potent renin inhibitors due to induced fit adaptation of the active site. , 1999, Bioorganic & medicinal chemistry letters.

[13]  R. Luther,et al.  Immediate blood pressure effects of the renin inhibitor enalkiren and the angiotensin-converting enzyme inhibitor enalaprilat. , 1991, American heart journal.

[14]  J. Ménard,et al.  Effects of Blocking the Angiotensin II Receptor, Converting Enzyme, and Renin Activity on the Renal Hemodynamics of Normotensive Guinea Pigs , 1993, Journal of cardiovascular pharmacology.

[15]  J. Wood,et al.  Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. , 2000, Chemistry & biology.

[16]  H. Kleinert,et al.  Renal hemodynamic and excretory responses to renin inhibition induced by A-64662. , 1990, The Journal of pharmacology and experimental therapeutics.

[17]  J. Wood,et al.  Inhibitors of renin as potential therapeutic agents. , 1987, Journal of enzyme inhibition.

[18]  L. Skeggs,et al.  THE PREPARATION, PURIFICATION, AND AMINO ACID SEQUENCE OF A POLYPEPTIDE RENIN SUBSTRATE , 1957, The Journal of experimental medicine.

[19]  N. Hollenberg,et al.  Renal circulation and blockade of the renin-angiotensin system. Is angiotensin-converting enzyme inhibition the last word? , 1995, Hypertension.

[20]  P. Anderson,et al.  Discovery of non-peptidic P2-P3 butanediamide renin inhibitors with high oral efficacy. , 1999, Bioorganic & medicinal chemistry.

[21]  M. James,et al.  Conformational flexibility in the active sites of aspartyl proteinases revealed by a pepstatin fragment binding to penicillopepsin. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[22]  F. Bühler,et al.  Blood Pressure Control by the Renin‐Angiotensin System in Normotensive Subjects: Assessment by Angiotensin Converting Enzyme and Renin Inhibition , 1992, Circulation.

[23]  G. Tunnicliff,et al.  Inhibition of enzymic reactions by transition state analogs: an approach for drug design. , 1981, General pharmacology.

[24]  N. Hollenberg,et al.  Responses to converting enzyme and renin inhibition. Role of angiotensin II in humans. , 1994, Hypertension.

[25]  J. Hall,et al.  Control of arterial pressure and renal function during chronic renin inhibition. , 1990, Journal of Hypertension.

[26]  J. Boger,et al.  Statine-containing renin inhibitor. Dissociation of blood pressure lowering and renin inhibition in sodium-deficient dogs. , 1984, Hypertension.

[27]  F. Gross,et al.  Inhibition of the Renin-Angiotensinogen Reaction by Pepstatin , 1972, Science.